The life sciences industry sits at the intersection between scientific innovation and advancements in healthcare and technology, so safeguarding these innovations in a rapidly evolving and highly competitive landscape is key. At Sterlington, our experienced attorneys leverage their deep technical industry knowledge and extensive litigation experience to both protect the intellectual property of our life sciences clients, and to defend and enforce their rights when required.
We represent life sciences companies in IP litigation, patent and regulatory strategy, commercial disputes, and transactions. Our Life Sciences clients range from start-ups developing cutting-edge technologies to producers of some of the world’s leading medicines.
Our IP trial lawyers have extensive experience representing branded pharmaceutical companies in patent litigation against generic manufacturers under the Hatch-Waxman Act, as well as advising biologic manufacturers under the Biologics Price Competition and Innovation Act. We also represent our Life Sciences clients in mergers, acquisitions, joint ventures, licenses, spinouts, financings, and other corporate transactions.
In addition to our deep experience with small-molecule products, pharmaceutical formulations, biologics, medical devices, and diagnostics, we have extensive experience with emerging technologies such as lipid nano-articles, chemically-modified biologics, CRISPR, CAR-T cells, and other novel drug technologies.